【新品上线】Cellectra™系列CD4、CD8 T细胞纳米分选磁珠：安全赋能，稳定高效

在细胞治疗领域，纳米磁珠的突破从未停歇。ACROBiosystems百普赛斯首-款实现“全自主技术闭环”的全新一代Cellectra™系列CD4、CD8 T细胞纳米分选磁珠正式问世！我们以技术创新为刃，直面行业在材料不对标、稳定性不足、批间差异明显、临床转化困难等核心痛点，经过多维度重复验证，以扎实数据与严苛标准为支撑，以临床级安全为核心，依托全自主技术闭环与高标准合规体系，为细胞分选提供安全、稳定、高效的一体化解决方案。

为什么选择Cellectra™系列产品？七大硬核实力给出答案：

ACROBiosystems百普赛斯现重磅推出Cellectra™系列CD4和CD8 T细胞纳米分选磁珠：

• 磁珠材质鉴定

Cellectra™ 系列纳米磁珠采用医疗级葡聚糖包裹的氧化铁纳米颗粒为原料，具备生物可降解性。磁珠能被抗葡聚糖单克隆抗体（anti-dextran mAb）识别。实验结果表明，ACROBiosystems百普赛斯与Company M的磁珠均呈抗葡聚糖抗体阳性，而另外两家商业化磁珠为阴性。由此证明，ACRO纳米磁珠生产关键原料信息真实可溯、安全特征清晰明确，能够为客户药物的生产与申报工作提供稳定可靠的材料保障。

Human PBMCs (4×107 total cells) were co-isolated using CD4 and CD8 Microbeads (recommended dosage) from Acro and other company products (Company M, Company T, Company G). Post-co-isolation cells from each manufacturer were stained with FITC anti-dextran antibody, PE anti-human CD3 antibody, and 7-AAD, then analyzed by flow cytometry. Notably, no dextran signal from bead-attached cells was detected for Company T or Company G.

Cellectra^TM Human CD4 NanoSort Microbeads

The CD4+ cells were isolated from 1×107human PBMCs using 20μL CellectraTM Human CD4 NanoSort Microbeads, Research grade (Cat. No. MBS-S004) , or other company products (Company M, Company T). The isolated cells and non-isolated cells were respectively stained using FITC anti-human CD4 antibody and 7-AAD, and then analyzed by Flow Cytometry.

Cellectra^TM Human CD8 NanoSort Microbeads

The CD8+ cells were isolated from 1×107 human PBMCs using 20μL CellectraTM Human CD8 NanoSort Microbeads, Research grade (Cat. No. MBS-S005), or other company products (Company M, Company T). The isolated cells and non-isolated cells were respectively stained using PE anti-human CD8 antibody and 7-AAD, and then analyzed by Flow Cytometry.

CD4 NanoSort Microbeads & CD8 NanoSort Microbeads

联合分选

Human PBMCs (per 107 cells) were isolated 20 μL CD4 NanoSort Microbeads (Cat. No. MBS-S004) and 20 μL CD8 NanoSort Microbeads (Cat. No. MBS-S005), in parallel with other company products (Company M, Company T). Both the isolated cells and non-isolated cells were stained with FITC anti-human CD4 antibody and PE anti-human CD8 antibody (top) and FITC anti-human CD3 antibody (bottom) as well as 7-AAD, and subsequently analyzed using Flow Cytometry.

• 优异的细胞分选性能

Isolation efficacy was validated using samples containing 1×10⁷ human PBMCs processed with the recommended dosage of Cellectra™ Human CD4 NanoSort Microbeads (Fig. A) or Cellectra™ Human CD8 NanoSort Microbeads (Fig. B), in parallel with other company products (Company M, Company T). Comparative analysis demonstrated that Acro NanoSort Microbeads achieved excellent high purity and recovery rates to other company products. Furthermore, high post-isolation cell viability was preserved, confirming suitability for sensitive downstream applications.

• 全方位稳定性验证

  多供体兼容性、多批次一致性验证

Minor inter-donor variability was observed in PBMC separation, with high purity and cell recovery consistently maintained (Fig. A). Three batches of CD4 or CD8 NanoSort Microbeads achieved consistent high purity and recovery, confirming robust batch-to-batch consistency and manufacturing reproducibility (Fig. B).

冻融和加速稳定性验证

Freeze-thaw stability was verified by subjecting the microbeads to 2–3 cycles prior to separation testing (Fig. A). Comparative analysis against the standard batch confirmed that purity and cell recovery were maintained at baseline specifications, demonstrating robust stability. To ensure prolonged shelf life, storage at -20°C or below is recommended upon receipt (however, repeated freeze-thaw cycles are not advised for routine operational use). 

Accelerated aging studies were conducted at 37°C to evaluate long-term stability profiles (Fig. B). Following 7 and 14-day incubation periods, the microbeads sustained high purity and cell recovery performance during PBMC separation. These data substantiate product stability and validate the established shelf-life specifications.

CD4、CD8纳米分选磁珠现开启试用装申请活动，扫码立即参与~